There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on SCYNEXIS (SCYX – Research Report) and Actinium Pharmaceuticals (ATNM – Research Report) with bullish sentiments.
In a report released yesterday, Jason McCarthy from Maxim Group reiterated a Buy rating on SCYNEXIS, with a price target of $4.00. The company’s shares closed last Monday at $1.19.
According to TipRanks.com, McCarthy is currently ranked with no stars on a 0-5 star ranking scale, with an average return of -21.4% and a 25.4% success rate. McCarthy covers the Healthcare sector, focusing on stocks such as Hancock Jaffe Laboratories, Lineage Cell Therapeutics, and Actinium Pharmaceuticals.
Currently, the analyst consensus on SCYNEXIS is a Strong Buy with an average price target of $5.13, a 327.5% upside from current levels. In a report released yesterday, Needham also maintained a Buy rating on the stock with a $5.00 price target.
Actinium Pharmaceuticals (ATNM)
JonesTrading analyst Matthew Cross maintained a Buy rating on Actinium Pharmaceuticals today and set a price target of $4.00. The company’s shares closed last Monday at $0.27, close to its 52-week low of $0.19.
According to TipRanks.com, Cross has currently no stars on a ranking scale of 0-5 stars, with an average return of -12.1% and a 33.6% success rate. Cross covers the Healthcare sector, focusing on stocks such as Catalyst Biosciences, Aldeyra Therapeutics, and Abeona Therapeutics.
Actinium Pharmaceuticals has an analyst consensus of Moderate Buy, with a price target consensus of $2.75, a 918.5% upside from current levels. In a report issued on October 24, Maxim Group also maintained a Buy rating on the stock with a $1.50 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.